Anna Kruschinski

1.0k total citations
26 papers, 711 citations indexed

About

Anna Kruschinski is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Anna Kruschinski has authored 26 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Molecular Biology and 9 papers in Genetics. Recurrent topics in Anna Kruschinski's work include Chemokine receptors and signaling (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (6 papers). Anna Kruschinski is often cited by papers focused on Chemokine receptors and signaling (10 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Multiple Myeloma Research and Treatments (6 papers). Anna Kruschinski collaborates with scholars based in United States, Italy and Austria. Anna Kruschinski's co-authors include Dirk Zboralski, Christian Maasch, Jan A. Burger, Julia Hoellenriegel, Michael J. Keating, William G. Wierda, Markus Chmielewski, Thomas Blankenstein, Hinrich Abken and Jehad Charo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Anna Kruschinski

25 papers receiving 687 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Kruschinski United States	11	376	329	307	102	77	26	711
Po Y. Ho United States	7	391 1.0×	855 2.6×	337 1.1×	67 0.7×	94 1.2×	17	1.2k
Steven K. Grossenbacher United States	15	514 1.4×	583 1.8×	175 0.6×	68 0.7×	43 0.6×	21	855
Clotilde Billottet France	14	268 0.7×	193 0.6×	408 1.3×	88 0.9×	47 0.6×	21	823
Elise Lavergne France	14	262 0.7×	263 0.8×	248 0.8×	29 0.3×	71 0.9×	16	665
George S. Laszlo United States	15	401 1.1×	208 0.6×	435 1.4×	224 2.2×	31 0.4×	35	814
Alexander W. Macfarlane United States	15	432 1.1×	534 1.6×	219 0.7×	89 0.9×	62 0.8×	30	940
Kristina Wikström Sweden	10	403 1.1×	226 0.7×	260 0.8×	88 0.9×	76 1.0×	22	675
Bhopal Mohapatra United States	14	174 0.5×	96 0.3×	438 1.4×	93 0.9×	58 0.8×	34	691
Dirk Zboralski United States	13	503 1.3×	218 0.7×	332 1.1×	135 1.3×	75 1.0×	22	937
Axel Hyrenius‐Wittsten Sweden	7	277 0.7×	117 0.4×	249 0.8×	179 1.8×	124 1.6×	11	621

Countries citing papers authored by Anna Kruschinski

Since Specialization

Citations

This map shows the geographic impact of Anna Kruschinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kruschinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kruschinski more than expected).

Fields of papers citing papers by Anna Kruschinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Kruschinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kruschinski. The network helps show where Anna Kruschinski may publish in the future.

Co-authorship network of co-authors of Anna Kruschinski

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Kruschinski. A scholar is included among the top collaborators of Anna Kruschinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Kruschinski. Anna Kruschinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ludwig, Heinz, Katja Weisel, Maria Teresa Petrucci, et al.. (2017). Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia. 31(4). 997–1000. 60 indexed citations

Weisberg, Ellen, Martin Sattler, Abdel Kareem Azab, et al.. (2017). Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget. 8(66). 109973–109984. 18 indexed citations

Zboralski, Dirk, Anna Kruschinski, Dirk Eulberg, & Axel Vater. (2016). CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids. Annals of Oncology. 27. vi371–vi371. 1 indexed citations

Enzmann, Volker, Stéphanie Lecaudé, Anna Kruschinski, & Axel Vater. (2016). CXCL12/SDF-1-Dependent Retinal Migration of Endogenous Bone Marrow-Derived Stem Cells Improves Visual Function after Pharmacologically Induced Retinal Degeneration. Stem Cell Reviews and Reports. 13(2). 278–286. 20 indexed citations

Jácamo, Rodrigo, Hong Mu, Qi Zhang, et al.. (2015). Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia. Blood. 126(23). 1348–1348. 12 indexed citations

Textor, Ana, Cynthia Pérez, Anna Kruschinski, et al.. (2014). Efficacy of CAR T-cell Therapy in Large Tumors Relies upon Stromal Targeting by IFNγ. Cancer Research. 74(23). 6796–6805. 58 indexed citations

Steurer, Michael, Lydia Scarfò, Marco Montillo, et al.. (2014). INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BENDAMUSTINE/RITUXIMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica. 99. 59–59. 2 indexed citations

Ludwig, Heinz, Katja Weisel, Maria Teresa Petrucci, et al.. (2014). Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. Blood. 124(21). 2111–2111. 7 indexed citations

Vater, Axel, Nicolaus Kröger, Stefan Zöllner, et al.. (2013). Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12. Clinical Pharmacology & Therapeutics. 94(1). 150–157. 63 indexed citations

10.

Chernikova, Sophia B., Jason H. Stafford, Taichang Jang, et al.. (2013). Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro-Oncology. 16(1). 21–28. 73 indexed citations

11.

Gobbi, Marco, Michael Steurer, Federico Caligaris‐Cappio, et al.. (2013). Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bendamustine and Rituximab In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL): Results From A Phase IIa Study. Blood. 122(21). 1635–1635. 8 indexed citations

12.

Girbl, Tamara, Josefina Piñón Hofbauer, Alexander Egle, et al.. (2013). The Spiegelmer® Nox-A12 Abrogates Homing Of Human CLL Cells To Bone Marrow and Mobilizes Murine CLL Cells In The Eμ-TCL1 Transgenic Mouse Model Of CLL. Blood. 122(21). 4111–4111. 2 indexed citations

13.

Stafford, Jason H., Milton Merchant, Taichang Jang, et al.. (2013). Abstract 385: Inhibition of recurrences of experimental brain tumors after irradiation by blocking the activity of SDF-1 (CXCL12) using the Spiegelmer® NOX-A12.. Cancer Research. 73(8_Supplement). 385–385. 1 indexed citations

14.

Ludwig, Heinz, Katja Weisel, Monika Engelhardt, et al.. (2013). Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and In Combination With Bortezomib and Dexamethasone In Patients With Relapsed Multiple Myeloma: Results From A Phase IIa Study. Blood. 122(21). 1951–1951. 6 indexed citations

15.

Hoellenriegel, Julia, Dirk Zboralski, Christian Maasch, et al.. (2013). The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 123(7). 1032–1039. 179 indexed citations

16.

Gobbi, Marco, Federico Caligaris‐Cappio, Marco Montillo, et al.. (2012). Phase IIa Study of the Anti-CXCL12/SDF-1 Spiegelmer® Nox-A12 Alone and Combined with Bendamustine/Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood. 120(21). 4593–4593. 3 indexed citations

17.

Roccaro, Aldo M., Antonio Sacco, Marco Ungari, et al.. (2012). In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. Blood. 120(21). 440–440. 3 indexed citations

18.

Merchant, Milton, et al.. (2012). Abstract 4382: Inhibition of SDF-1 (CXCL12) using the Spiegelmer NOX-A12 markedly delays the recurrence of ENU-induced rat brain tumors following irradiation. Cancer Research. 72(8_Supplement). 4382–4382. 1 indexed citations

19.

Hoellenriegel, Julia, Dirk Zboralski, Zeev Estrov, et al.. (2011). The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,. Blood. 118(21). 3878–3878. 3 indexed citations

20.

Kruschinski, Anna, Andreas Moosmann, Isabel Poschke, et al.. (2008). Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proceedings of the National Academy of Sciences. 105(45). 17481–17486. 158 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact